Taro Pharmaceutical Industries (NYSE:TARO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a report published on Saturday. The firm issued a strong-buy rating on the stock.

Separately, HC Wainwright lowered Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 price objective for the company. in a research report on Thursday, January 18th.

Taro Pharmaceutical Industries Stock Up 0.1 %

Shares of NYSE:TARO opened at $42.51 on Friday. The company’s fifty day moving average is $42.15 and its two-hundred day moving average is $40.16. The company has a market cap of $1.60 billion, a P/E ratio of 34.84 and a beta of 0.61. Taro Pharmaceutical Industries has a 12-month low of $24.69 and a 12-month high of $45.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TARO. Allspring Global Investments Holdings LLC acquired a new stake in shares of Taro Pharmaceutical Industries in the third quarter worth about $65,000. PenderFund Capital Management Ltd. acquired a new stake in Taro Pharmaceutical Industries in the 4th quarter worth approximately $92,000. Strs Ohio boosted its position in Taro Pharmaceutical Industries by 58.8% during the third quarter. Strs Ohio now owns 2,700 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares during the period. FNY Investment Advisers LLC acquired a new position in Taro Pharmaceutical Industries during the fourth quarter valued at approximately $105,000. Finally, SG Americas Securities LLC bought a new position in shares of Taro Pharmaceutical Industries in the third quarter valued at approximately $141,000. Hedge funds and other institutional investors own 91.40% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.